Clinical trials: Injections, Spinal
Degenerative Disc Disease
Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain
This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the safety and efficacy of Mesoblast's rexlemestrocel-L alone or combined with hyaluronic acid (HA) in…
- Trial name
- MSB-DR003 (NCT02412735)
- Testing
- Rexlemestrocel-L, Rexlemestrocel-L + HA Mixture
- Where
- 48 sites in United States, Australia
- Volunteers
- 404 people
- Sponsor
- Mesoblast, Ltd.
Acute Spinal Cord Injury
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)
The purpose of this research study is to gather scientific information about the effectiveness of the study drug, SUN13837 Injection, when compared with the placebo (inactive substance) in participants with acute spinal cord…
- Trial name
- NCT01502631
- Testing
- SUN13837 injection
- Where
- 67 sites in United States, Canada and 5 more
- Volunteers
- 65 people
- Sponsor
- Daiichi Sankyo
Amyotrophic Lateral Sclerosis, ALS
Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow-derived stem cells("HYNR-CS inj"), through intrathecal delivery for the treatment in patients with ALS. This study consists of 2 steps.
- Trial name
- NCT01363401
- Testing
- HYNR-CS inj, Control group
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Corestemchemon, Inc.
Arthritis, Psoriatic
Study Evaluating the Safety of Enbrel (Etanercept)
The purpose of this study is to collect post-marketing information on the safety of Enbrel in Filipino patients.
- Trial name
- NCT00683384
- Testing
- Etanercept (Enbrel)
- Where
- Philippines
- Volunteers
- 93 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Arthritis, Psoriatic
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and…
- Trial name
- NCT01490450
- Testing
- BMS-945429
- Where
- 49 sites in United States, Argentina and 11 more
- Volunteers
- 165 people
- Sponsor
- CSL Behring
Anklyosing Spondylitis
16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
This study assessed the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who were tolerant to or had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor
- Trial name
- MEASURE2 (NCT01649375)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 53 sites in United States, Austria and 11 more
- Volunteers
- 219 people
- Sponsor
- Novartis Pharmaceuticals
Brain Diseases, Spinal Cord Diseases
Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine.
- Trial name
- NCT00862459
- Testing
- Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
- Where
- 27 sites in United States, Argentina and 2 more
- Volunteers
- 237 people
- Sponsor
- Bayer
Degenerative Joint Disease, Congenital Deformity
Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
STUDY OBJECTIVES: To demonstrate equivalent clinical and radiologic outcomes as "gold standard" (Autologous Bone Graft) in a representative clinical model (hindfoot fusions) STUDY HYPOTHESIS: Augment® Injectable is an equivalent…
- Conditions
- Degenerative Joint Disease, Congenital Deformity, Arthritis, Osteoarthritis
- Trial name
- NCT01305356
- Testing
- Augment® Injectable Bone Graft, Autologous bone graft
- Where
- 25 sites in United States, Canada
- Volunteers
- 299 people
- Sponsor
- BioMimetic Therapeutics
Rheumatoid Arthritis, Psoriatic Arthritis
Surveillance of Humira Injection in Korean Patients
Patients who take Humira as prescribed by physicians as per Korean label will be enrolled and observed in normal medical practice setting for not less than 3 months following first dose of Humira.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- NCT01083121
- Where
- 77 sites in South Korea
- Volunteers
- 1,779 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Amyotrophic Lateral Sclerosis
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS.
- Trial name
- NCT00326625
- Testing
- 40 mg glatiramer acetate
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 366 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
Psoriatic Arthritis
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
The purpose of this study is to compare subcutaneous Abatacept to placebo in the treatment of psoriatic arthritis
- Trial name
- ASTRAEA (NCT01860976)
- Testing
- Abatacept
- Where
- 82 sites in United States, Argentina and 15 more
- Volunteers
- 489 people
- Sponsor
- Bristol-Myers Squibb
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- ERASURE (NCT01365455)
- Testing
- secukinumab 150 mg
- Where
- 88 sites in United States, Argentina and 10 more
- Volunteers
- 738 people
- Sponsor
- Novartis Pharmaceuticals
Spondylitis, Ankylosing
Extension in AS: Sustainability of Benefits, Safety and Tolerability
This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as…
- Trial name
- MEASURE 1 ext (NCT01863732)
- Testing
- Secukinumab
- Where
- 56 sites in United States, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis
The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese patients with ankylosing spondylitis
- Trial name
- NCT01248793
- Testing
- Golimumab
- Where
- 7 sites in China
- Volunteers
- 213 people
- Sponsor
- Centocor, Inc.
Psoriatic Arthritis
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after…
- Trial name
- NCT04109976
- Testing
- Bimekizumab
- Where
- 47 sites in United States, Czechia and 4 more
- Volunteers
- 214 people
- Sponsor
- UCB Biopharma SRL
Spondylitis, Ankylosing
A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
The purpose of this study is to evaluate the safety and efficacy of subcutaneous injections (under the skin) of golimumab for the treatment of active ankylosing spondylitis [AS(arthritis of the spine)].
- Trial name
- NCT00265083
- Testing
- golimumab
- Where
- 39 sites in United States, Belgium and 7 more
- Volunteers
- 356 people
- Sponsor
- Centocor, Inc.
Lumbar Disc Herniation
SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)
This study is to evaluate the effectiveness of a single-dose intervertebral disc injection of SI-6603 in subjects with lumbar disc herniation (LDH)
- Trial name
- NCT03607838
- Testing
- SI-6603
- Where
- 67 sites in United States
- Volunteers
- 352 people
- Sponsor
- Seikagaku Corporation
Arthritis, Psoriatic
A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis
The purpose of this study is to evaluate the safety and efficacy (improvement of signs and symptoms) of subcutaneous (under the skin) injections of golimumab for the treatment of active psoriatic arthritis (PsA).
- Trial name
- GO-REVEAL (NCT00265096)
- Testing
- golimumab
- Where
- 51 sites in United States, Belgium and 4 more
- Volunteers
- 407 people
- Sponsor
- Centocor, Inc.
Spondylitis, Ankylosing
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.
- Trial name
- MEASURE 3 (NCT02008916)
- Testing
- Secukinumab
- Where
- 57 sites in United States, Belgium and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Spinal Stenosis, Lumbar Region, With Neurogenic Claudication
The MiDAS ENCORE Study
Study Objective: To compare patient outcomes following treatment with either the MILD procedure or epidural steroid injections (ESIs) in patients with painful lumbar spinal stenosis exhibiting neurogenic claudication and having…
- Trial name
- NCT02093520
- Testing
- MILD Procedure, Epidural Steroid Injection
- Where
- 12 sites in United States
- Volunteers
- 302 people
- Sponsor
- Vertos Medical, Inc.